Kriya Therapeutics appoints Pedro Huertas as CMO

Fully integrated gene therapy company Kriya Therapeutics has appointed Pedro Huertas, M.D., Ph.D., as Chief Medical Officer of its Rare Disease Division.

Dr Huertas will be responsible for directing and executing the companies clinical, medical and scientific plans in order to advance its rare disease pipeline.

Dr Huertas has three decades of experiences in advancing therapies for rare conditions, having held positions in preclinical and clinical research, clinical development, post-marketing development and regulatory strategy.

Dr Huertas previously served as CMO at Pharma, Sentien Biotechnologies and Eloxx Pharmaceuticals.

He also held clinical an development roles at Pfizer, Shire, Amicus and Genzyme Corp.

Shankar Ramaswamy, M.D., Co-Founder and Chief Executive Officer of Kriya, said:

“Pedro brings a wealth of experience to Kriya as we continue to advance our rare disease gene therapy portfolio.

“His track record of success in developing impactful medicines has earned him the respect of the rare disease community – and we look forward to supporting him within our unique ecosystem to deliver transformative gene therapies to patients.”

Dr Huertas said:

“I’m excited to join a company with the potential to deliver several innovative, life-changing therapies to patients with rare diseases.

“Kriya’s fully integrated technology platform, advanced manufacturing capabilities and accomplished team offer significant advantages as it pursues its mission – and I am eager to deploy these capabilities to accelerate the delivery of gene therapies to patients who need them.”

Kriya is pioneering novel technologies and therapeutics in the gene therapy field.

The company aims to revolutionise the design, development and manufacturing of gene therapies to improve speed to market and significantly reduce costs.